Cefamandole lithium
Cefamandole (Cephamandole) lithium is a semi-synthetic second-generation cephalosporin antibiotic with broad-spectrum antimicrobial activity. Cefamandole lithium is resistant to hydrolysis by β-lactamases produced by some Gram-negative bacteria. Cefamandole lithium kills Gram-positive cocci and various Gram-negative bacilli mainly by inhibiting cell wall synthesis, but it is inactive against Pseudomonas, Proteus vulgaris and Providencia stuartii, and its efficacy is affected by inoculum size. The plasma elimination half-life of Cefamandole lithium in rats is only 0.4 h, it is mainly excreted in urine in biologically active form, and it hardly penetrates the non-inflamed blood-brain barrier. Cefamandole lithium is widely used in studies related to bacterial infections.
For research use only. We do not sell to patients.
- CAS No.: 58648-57-0
- Formula: C18H17LiN6O5S2
- Molecular Weight:468.44
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Antibiotic Isoforms
More
Biological Activity
Description
In Vitro
Cefamandole lithium (30 μg/mL; 0, 1, 3, 6, 12 h) is hydrolyzed by beta-lactamases from Enterobacter cloacae, Serratia marcescens, and Proteus morganii, allowing bacterial growth to resume after hydrolysis is complete, while Pseudomonas aeruginosa grows despite cefamandole presence prior to hydrolysis[1].
Cefamandole lithium (0.12-64 μg/mL; 18 h) inhibits 90-100% of methicillin-susceptible S. aureus, group A and B streptococci, S. pneumoniae, N. gonorrhoeae, H. influenzae, and S. typhosa[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Cefamandole (50 mg/kg; intravenous administration; single dose) lithium exhibits free drug pharmacokinetic characteristics consistent with a two-compartment model in male Sprague-Dawley rats, with an elimination half-life of 21.6 min[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 58648-57-0
-
Molecular Weight 468.44
-
Formula C18H17LiN6O5S2
-
SMILES
O=C(C(N12)=C(CSC3=NN=NN3C)CS[C@]2([H])[C@H](NC([C@H](O)C4=CC=CC=C4)=O)C1=O)O[Li]
-
Synonyms
Cephamandole lithium
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Protocol for Pharmacokinetic Study
Pharmacokinetic studies quantify how an organism handles a drug over time through absorption, distribution, metabolism, and excretion, and the core experimental readout is the concentration-time profile of parent drug and, when relevant, metabolites in biological matrices such as plasma, whole blood, urine, bile, or tissue. Pharmacokinetic analysis links dose, route, exposure, clearance, half-life, distribution, bioavailability, and systemic exposure to drug efficacy and toxicity hypotheses rather than measuring a signaling pathway directly. The literature links pharmacokinetics to drug-development phenotypes by showing that drug metabolism and pharmacokinetics influence compound progression, exposure-response interpretation, safety margins, dosing strategy, and failure risk during discovery and development. DMPK science contributes to compound optimization by integrating physicochemical properties, in vitro metabolism, transporter behavior, in vivo exposure, and pharmacodynamic contex
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
Purity & Documentation
References
[1]. Neu HC, et al. Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity. Antimicrob Agents Chemother. 1974;6(2):177-182. [Content Brief]
[2]. Eykyn S, et al. Antibacterial activity of cefamandole, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cephalexin. Antimicrob Agents Chemother. 1973;3(6):657-661. [Content Brief]
[3]. Griffith RS, et al. Cefamandole: in vitro and clinical pharmacokinetics. Antimicrob Agents Chemother. 1976;10(5):814-823. [Content Brief]
[4]. Lee FH, et al. Comparative tissue distribution of ceforanide, cefazolin, and cefamandole in rats. Antimicrob Agents Chemother. 1981;19(4):625-627. [Content Brief]
[5]. Yeh PH, et al. Determination of unbound cefamandole in rat blood by microdialysis and microbore liquid chromatography. Biomed Chromatogr. 2001;15(1):14-17. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)